Source: Annual Congress 2013 –Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
B. H. Kang, T. S. Shim, S. D. Lee, W. S. Kim, D. S. Kim (Seoul, Republic Of Korea). Current status of fluoroquinolone use for treatment of tuberculosis in Korea. Eur Respir J 2013; 42: Suppl. 57, 2822

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Risk factors for anti-TB drug resistance in Poland Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013 Prevalence of fluoroquinolone resistance in mycobacterium tuberculosis in a tertiary care hospital in India Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/Germany Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Risk factors for acquired drug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014